Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Blood (2024) 144 (Supplement 1): 4422.

https://doi.org/10.1182/blood-2024-211078

Published: 2024

Journal Articles

Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Lucía Pérez-Lamas, Adrian Segura Diaz, Regina García Delgado, Alberto Alvarez-Larran, María Alicia Senin, Elvira Mora, Maria Laura Fox, Irene Pastor Galan, Gemma Azaceta, Sara Garrido Paniagua, Raul Perez Lopez, Diana Margarita Trejos Carvajal, Anna Angona, Carmen Albo Lopez, Pablo Lorente Alegre, Míriam Vara, Juan Antonio Juan Vera Goñi, Dunia De Miguel Llorente, Angeles Fernández Rodríguez, Alberto Marin Sanchez, Adriana Hernando Megido, Maria Teresa Gómez Casares, Ruth Stuckey, Gonzalo Carreño, Natalia De Las Heras Rodriguez, Blanca Xicoy, Manuel Perez Encinas, Raquel Mata Serna, Lucia Nuñez Martin-Buitrago, Francisca Ferrer Marin, Neus Amer Salas, Carolina Guillén Rienda, Patricia Velez, Laura Lamarca Eraso, Sandra Martín, Iryna Luts Khoroz, Erik De Cabo López, Angela Gil, Sofía Martín-Consuegra Ramos, Fernando Marco De Lucas, Maria José Otero Martinez-Fornes, María Luisa Martín Mateos, Teresa Arquero, Elena Cabezudo Pérez, Luis Antonio López Gómez, Angela Martinez Hellin, Aurelia Tejedor, Esther Herrera de Pablo, Maria Isabel Mata Vazquez, Inmaculada Castillo Valero, Maria Jose Fernández, Carlos Aguilar, Marta Santaliestra, Antonio Garcia Menchon, Begona Navas Elorza, Maria Antonia Duran, María Pérez Sala, Teresa Hernández Santamaría, Mª Ángeles Muñoz Jarreño, Julio Dávila-Valls, Williana Torres Jiménez, Joan Alfons Gonzálvez Fernández, Hugo Alexander Torres Mantilla, Teresa Cobo Rodríguez, Aitor Abuin Blanco, Francisco Pérez, María José Llácer Ferrandis, Paola Beneit Villena, Raisa Peralta, Federico Herrera, Eloi Cañamero Giro, Reyes Jimenez Barcenas, Mercedes Gasior Kabat, Sonia González De Villambrosia, Mariana Teresa Tercero-Mora Rodriguez, Marina Menéndez Cuevas, Beatriz Cuevas Ruiz, Marta Fonseca-Santos, Sonia Garcés Piquer, Rosalía Delapuerta, Alvaro Lorenzo Vizcaya, Juan Carlos Hernandez Boluda, Valentín García Gutiérrez, Sr.

Blood (2024) 144 (Supplement 1): 1790.

https://doi.org/10.1182/blood-2024-200698

Published: 2024

Journal Articles

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Blood (2024) 144 (Supplement 1): 4403.

https://doi.org/10.1182/blood-2024-209936

Published: 2024

Journal Articles

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Antonio Gutiérrez, Izaskun Zeberio, Pilar Martinez-Barranco, Francisco Javier Peñalver, Sandra Pérez, Daniel Morillo, Xabier Mart N Martitegui, Concepción Nicolás, Ainara Ferrero, Ana Jiménez Ubieto, Mariana Bastos-Oreiro, Julio Dávila-Valls, Maria Victoria Calle Gordo, María Pérez Sala, Guillermo Rodríguez Garcia, Aranzazu Alonso Alonso, Ana Garcia Noblejas, Diana Sanchez Arguello, Teresa Knight Asorey, Maria Angeles Fernandez Fernandez, Javier López Marin, Jaime Perez de Oteyza, Sonia González De Villambrosia, Elena Perez Ceballos, Alejandro Marin, Belén Navarro, Ruben Fernandez Alvarez, Pilar Gómez, Jose Antonio Hueso, Maria Jesus Penarrubia Ponce, Pilar Bravo, Daniel García Belmonte, Haridian De La Nuez Melian, Sara Nistal, Pau Abrisqueta Costa, Fernanda Ibañez, Luis Palomera, Eva Donato, Andrea Provencio Rincon, Maria Stefania Infante, Eva Gonzalez Barca

Blood (2024) 144 (Supplement 1): 2356.

https://doi.org/10.1182/blood-2024-210868

Published: 2024

Journal Articles

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Blood (2024) 144 (Supplement 1): 3109.

https://doi.org/10.1182/blood-2024-207895

Published: 2024

Journal Articles

Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Blood (2024) 144 (Supplement 1): 1715.

https://doi.org/10.1182/blood-2024-199742

Published: 2024

Journal Articles

First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 1992.

https://doi.org/10.1182/blood-2024-204614

Published: 2024

Journal Articles

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Blood (2023) 142 (Supplement 1): 4870.

https://doi.org/10.1182/blood-2023-186594

Published: 2023

Journal Articles

Genetic Subtyping Using Whole Exome Sequencing across Large B Cell Lymphoma Entities in a Series of 109 DLBCL and Plasmablastic Lymphoma Cases

Santiago Montes-Moreno, Sr., Aitana Avendaño, Sonia Gonzalez De Villambrosia, Laura Rodriguez-Merino, Jordi Morata, Raul Tonda, Estrella Carrillo-Cruz, Carlos Grande, Jose Maria Roncero, Jaime Perez De Oteyza, Concepcion Nicolas, Beatriz Rey Búa, Pau Abrisqueta, Antonio Gutierrez, Angel Ramirez, Alejandro Martin Garcia-Sancho, Eva Maria Gonzalez Barca

Blood (2023) 142 (Supplement 1): 6092.

https://doi.org/10.1182/blood-2023-179150

Published: 2023

Journal Articles

Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)

Fernando Martín Moro, Leyre Bento De Miguel, Juan Marquet Palomanes, Antonio Gutierrez, Antonio Diaz-Lopez, Jose M. Sanchez, Jose Antonio Garcia Vela, Antonio Salar, Raul Cordoba, Silvana Novelli, Maria J. Rodriguez-Salazar, Sonia González de Villambrosia, Raquel Del Campo, Hugo Daniel Luzardo Henriquez, Daniel Garcia, Juan-Manuel Sancho, Pau Abrisqueta, Alejandro Martín García-Sancho, Mariana Bastos-Oreiro

Blood (2022) 140 (Supplement 1): 779–781.

https://doi.org/10.1182/blood-2022-170854

Published: 2022

Journal Articles

Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group

Mariana Bastos-Oreiro, Ana Jimenez-Ubieto, Sonia González de Villambrosia, Raul Cordoba, Elena Pérez Ceballos, EVA Maria DONATO Martin, Ana Muntañola Prat, Hugo Daniel Luzardo Henriquez, Lourdes Escoda, Maria Jesús Peñarrubia, María Pozas, Alberto Lopez-Garcia, Daniel Garcia, Emilia Pardal, Claudia Salazar Lozada, Alejandro Martín García-Sancho

Blood (2022) 140 (Supplement 1): 9501–9503.

https://doi.org/10.1182/blood-2022-166213

Published: 2022

Journal Articles

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Blood (2022) 140 (Supplement 1): 826–827.

https://doi.org/10.1182/blood-2022-158669

Published: 2022

Journal Articles

Rituximab Maintenance after R-Bendamustine or R-CHOP in First-Line Treatment of Low-Grade Follicular Lymphoma: A Multicentre, Retrospective Study of the Spanih Group Geltamo

Mariana Bastos-Oreiro, Antonio Gutierrez, Almudena Cabero Martínez, Javier López Jiménez, Paola Sandra Villafuerte Gutierrez, Ana Jimenez-Ubieto, Adolfo De La Fuente, Belén Navarro, Maria Stefania Infante, Raul Cordoba, Jaime Perez De Oteyza, Sonia González de Villambrosia, Raquel Del Campo, Daniel Garcia, Antonio Salar, Juan-Manuel Sancho

Blood (2022) 140 (Supplement 1): 3618–3619.

https://doi.org/10.1182/blood-2022-166027

Published: 2022

Journal Articles

Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group

Blood (2022) 140 (Supplement 1): 9347–9349.

https://doi.org/10.1182/blood-2022-160073

Published: 2022

Journal Articles

Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo

Blood (2021) 138 (Supplement 1): 2497.

https://doi.org/10.1182/blood-2021-148361

Published: 2021

Journal Articles

Rreal-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study

Blood (2021) 138 (Supplement 1): 3850.

https://doi.org/10.1182/blood-2021-147670

Published: 2021

Journal Articles

Cell Free Tumor DNA for DLBCL Genotyping in a Phase II Randomized Trial Comparing Standard RCHOP Versus Brcap As First Line Treatment in Patients with Poor IPI DLBCL

Nerea Martinez, PhD, Sonia González de Villambrosia, MD, Ainara Pereña, Raul Tonda, Sergi Beltran, PhD, Marta Gut, PhD, Estrella Carrillo-Cruz, MD, Carlos Grande, MD, Alejandro Martín, MD, Concepcion Nicolas, MD, Jose Maria Roncero, MD, Maria J. Rodriguez-Salazar, MD, Jaime Perez De Oteyza, MDPhD, Eulogio Conde, MD PhD, Eva Gonzalez-Barca, Santiago Montes-Moreno, MD PhD

Blood (2018) 132 (Supplement 1): 1676.

https://doi.org/10.1182/blood-2018-99-113757

Published: 2018

Journal Articles

Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group

Blood (2018) 132 (Supplement 1): 1637.

https://doi.org/10.1182/blood-2018-99-110792

Published: 2018

Journal Articles

New Prognosis Score Including Absolute Lymphocytes/Monocytes Ratio and Beta2microglobulin in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO)

Blood (2018) 132 (Supplement 1): 347.

https://doi.org/10.1182/blood-2018-99-118719

Published: 2018

Journal Articles

Post-Transplantation Cyclophosphamide Versus Low Doses ATG Fresenius As Part of Two Immunosuppression Regimens for Graft Versus Host Disease Prophylaxis: Low Severe Graft Versus Host Disease (GVHD) Incidence and y Similar Gvhd-Free and Relapse-Free Survival (GRFS)

Cristina Fernández Martínez, Arancha Bermúdez, MD, Sara García Ávila, MD, Borja San Pedro, Almudena Cabero Martínez, MD, Lucrecia Yáñez, MD PhD, Mónica López Duarte, Mercedes Colorado, MD, Sonia González de Villambrosia, MD, Joan Manuel Mora, MD, Yolanda Gonzalez Romero, MD, David Gomez, MD, Sara Fenandez Luis, MD, Irati Ormazabal, MD, Andrés Insunza, Iñigo Romon, MD PhD, Jose Luis Arroyo, MD, Eulogio Conde, MD PhD, Carlos Richard, MD

Blood (2018) 132 (Supplement 1): 5716.

https://doi.org/10.1182/blood-2018-99-114124

Published: 2018

NARROW

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Genetic Subtyping Using Whole Exome Sequencing across Large B Cell Lymphoma Entities in a Series of 109 DLBCL and Plasmablastic Lymphoma Cases

Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)

Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Rituximab Maintenance after R-Bendamustine or R-CHOP in First-Line Treatment of Low-Grade Follicular Lymphoma: A Multicentre, Retrospective Study of the Spanih Group Geltamo

Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group

Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo

Rreal-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study

Cell Free Tumor DNA for DLBCL Genotyping in a Phase II Randomized Trial Comparing Standard RCHOP Versus Brcap As First Line Treatment in Patients with Poor IPI DLBCL

Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group

New Prognosis Score Including Absolute Lymphocytes/Monocytes Ratio and Beta2microglobulin in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO)

Post-Transplantation Cyclophosphamide Versus Low Doses ATG Fresenius As Part of Two Immunosuppression Regimens for Graft Versus Host Disease Prophylaxis: Low Severe Graft Versus Host Disease (GVHD) Incidence and y Similar Gvhd-Free and Relapse-Free Survival (GRFS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only